Group 1 - The core point of the article is that Zhendong Pharmaceutical announced the release of a portion of shares pledged by its controlling shareholder, Shanxi Zhendong Health Industry Group Co., Ltd. [2] - The number of shares released from pledge is 26,404,495 shares [2]

山西振东制药股份有限公司（以下简称"公司"或"本公司"）于 近日接到控股股东山西振东健康产业集团有限公司（以下简称"振 东集团"）通知，获悉其所持有的本公司部分股份解除质押，具体 事项如下： 一、股东股份解押基本情况 | 股东名称 | 是否为控 股股东 | 本次解押数量 （股） | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 比例 | 比例 | | | | | 振东集团 | 是 | 26,404,495 | 8.74% | 2.63% | 2024.09.13 | 2025.09.03 | 晋商银行股份有限公司 长治分行 | | 合计 | | 26,404,495 | 8.74% | 2.63% | | | | 证券代码：300158 证券简称：振东制药 公告编号：2025-052 山西振东制药股份有限公司 关于股东股份解押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、本次解除质押基本情况 特此公告 ...

Company Overview - Shanxi Zhendong Pharmaceutical Co., Ltd. was established on November 15, 1995, and listed on January 7, 2011. The company is located in Changzhi City, Shanxi Province [2] - The main business includes the research, production, and sales of generic and innovative drugs related to oncology, hair, digestion, urology, and cardiovascular diseases, as well as a full industry chain for traditional Chinese medicine [2] - The revenue composition is as follows: Traditional Chinese medicine accounts for 54.82%, chemical drugs for 43.10%, other for 1.98%, sales materials for 0.10%, and research income for 0.00% [2] Financial Performance - For the first half of 2025, the company achieved operating revenue of 1.457 billion yuan, a year-on-year decrease of 3.30%. The net profit attributable to the parent company was 7.9313 million yuan, down 74.13% year-on-year [2] - Since its A-share listing, the company has distributed a total of 3.372 billion yuan in dividends, with no dividends distributed in the last three years [3] Stock Performance - As of September 3, the stock price of Zhendong Pharmaceutical was 8.42 yuan per share, with a market capitalization of 8.465 billion yuan. The stock has increased by 94.91% year-to-date, but has decreased by 4.43% in the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on August 11, where it recorded a net purchase of 866.539 million yuan [1] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 7.9704 million shares, an increase of 5.0578 million shares compared to the previous period [3]

Group 1 - The company Shanxi Zhendong Pharmaceutical Co., Ltd. announced the progress of its share repurchase plan as of August 31, 2025 [1] - The share repurchase plan was approved on October 22 and November 12, 2024, with a total repurchase fund limit of 100 million yuan and a minimum of 50 million yuan, at a price not exceeding 6 yuan per share [2] - The maximum repurchase price was later adjusted to not exceed 11.4 yuan per share, while other terms remained unchanged [2] Group 2 - As of August 31, 2025, the company repurchased a total of 13.0167 million shares, accounting for 1.29% of the total share capital, with a total transaction amount of 52.0309 million yuan [3] - The highest transaction price was 10.06 yuan per share, and the lowest was 3.51 yuan per share [3] - The company's share repurchase activities complied with relevant regulations and guidelines [4]

Summary of Key Points Core Viewpoint - Zhendong Pharmaceutical announced a share buyback plan, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Group 1: Share Buyback Details - As of August 31, 2025, the company has repurchased a total of 13,016,700 shares, which represents 1.29% of the current total share capital [1] - The maximum purchase price for the shares was RMB 10.06 per share, while the minimum purchase price was RMB 3.51 per share [1] - The total amount spent on the share buyback reached RMB 52,030,929, excluding transaction fees [1]

Group 1 - The company, Zhendong Pharmaceutical, announced a share buyback of approximately 13.02 million shares, representing 1.29% of its total share capital, with a total expenditure of about 52.03 million RMB [1] - The highest and lowest prices for the share buyback were 10.06 RMB and 3.51 RMB per share, respectively [1] - As of the report date, the market capitalization of Zhendong Pharmaceutical is 8.6 billion RMB [1] Group 2 - For the first half of 2025, the revenue composition of Zhendong Pharmaceutical is as follows: pharmaceutical production and sales accounted for 110.27%, herbal planting industry for 31.67%, and technical services for 3.38%, with inter-segment eliminations at -45.32% [1]

格隆汇9月2日丨振东制药(300158.SZ)公布，截至2025年8月31日，公司累计通过股份回购专用证券账户 以集中竞价交易方式回购公司股份13,016,700股，占公司目前总股本比例为1.29%，回购最高成交价为 人民币10.06元/股，回购最低成交价为人民币3.51元/股，成交总金额为人民币5203.0929万元(不含交易 费用)。 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-051 山西振东制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"） 分别于 2024 年 10 月 22 日、11 月 12 日召开公司第六届董事会第二 次会议、2024 年第二次临时股东大会，审议通过了《关于回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分股份，回购的股份将全部用于注销并减少公司注册资本。本 次用于回购股份的资金总额上限为人民币 10,000 万元，回购下限为 人民币 5,000 万元，回购价格不超过人民币 6.00 元/股（含本数）， 回购股份的实施期限为自公司股东大会审议通过本次回购股份方案 之日起不超过 12 个月。具体内容详见公司于 2024 年 10 月 24 日、2024 年 11 月 12 日刊登在巨潮资讯网（www.cninfo.com.cn）的相关公告。 公司于 2025 年 8 月 25 日召开第六届董事会第五次会议，审议通 过了 ...

Core Viewpoint - The article emphasizes the importance of corporate social responsibility (CSR) as a fundamental aspect of business strategy, highlighting the exemplary role of Zhendong Pharmaceutical in addressing social needs and contributing to community development through various initiatives [2][7]. Group 1: Support for Special Groups - Zhendong Pharmaceutical prioritizes the transition and development of retired military personnel, implementing a comprehensive support system that includes preferential hiring and skill development [3]. - The company has organized special recruitment events for veterans, resulting in 420 veterans joining the workforce, many of whom have advanced to key management positions [3]. - A regular care mechanism for veterans has been established, including annual forums and military skill exhibitions, fostering a strong sense of community and shared purpose within the company [3][4]. Group 2: Commitment to Public Welfare - Zhendong Pharmaceutical has developed a comprehensive public welfare system that encompasses rural revitalization, educational support, and disaster relief, focusing on long-term impact [5]. - The company has created a closed-loop operational mechanism for rural revitalization, providing free training and resources to farmers, which has led to an average annual income increase of 18,000 yuan per household in Ping Shun County [5]. - The company has a long-standing commitment to various charitable activities, including support for underprivileged students and disaster relief efforts, demonstrating its dedication to social welfare [6]. Group 3: Corporate Culture and Values - The company integrates military values into its corporate culture, conducting military training for employees to enhance discipline and teamwork [4]. - Zhendong Pharmaceutical's core values emphasize shared prosperity with the community and nation, guiding its CSR initiatives and business practices [6][7]. - The company aims to continue evolving its CSR practices, focusing on precision and systematic approaches to enhance its social impact [6].

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]